Herve Hoppenot
Net Worth

Last updated:

What is Herve Hoppenot net worth?

The estimated net worth of Mr. Herve Hoppenot is at least $45,140,495 as of 23 Feb 2021. He owns shares worth $24,290,381 as insider, has earned $450,114 from insider trading and has received compensation worth at least $20,400,000 in Incyte Corporation.

What is the salary of Herve Hoppenot?

Mr. Herve Hoppenot salary is $2,550,000 per year as Chairman, Pres & Chief Executive Officer in Incyte Corporation.

How old is Herve Hoppenot?

Mr. Herve Hoppenot is 65 years old, born in 1960.

What stocks does Herve Hoppenot currently own?

As insider, Mr. Herve Hoppenot owns shares in one company:

Company Title Shares Price per share Total value
Incyte Corporation (INCY) Chairman, Pres & Chief Executive Officer 284,231 $85.46 $24,290,381

What does Incyte Corporation do?

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in various liquid and solid tumor types; and ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and philadelphia-chromosome positive acute lymphoblastic leukemia. Its clinical stage products include ruxolitinib, a steroid-refractory chronic graft-versus-host-diseases (GVHD); itacitinib, which is in Phase II/III clinical trial to treat naive chronic GVHD; and pemigatinib for treating bladder cancer, cholangiocarcinoma, myeloproliferative syndrome, and tumor agnostic. In addition, the company engages in developing Parsaclisib, which is in Phase II clinical trial for follicular lymphoma, marginal zone lymphoma, and mantel cell lymphoma. Additionally, it develops Retifanlimab that is in Phase II clinical trials for MSI-high endometrial cancer, merkel cell carcinoma, and anal cancer, as well as in Phase II clinical trials for patients with non-small cell lung cancer. It has collaboration agreements with Novartis International Pharmaceutical Ltd.; Eli Lilly and Company; Agenus Inc.; Calithera Biosciences, Inc; MacroGenics, Inc.; Merus N.V.; Syros Pharmaceuticals, Inc.; Innovent Biologics, Inc.; Zai Lab Limited; Cellenkos, Inc.; and Nimble Therapeutics, as well as clinical collaborations with MorphoSys AG and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was incorporated in 1991 and is headquartered in Wilmington, Delaware.

INCY logo
INCY
Incyte Corporation
$85.46

Herve Hoppenot insider trading

Incyte Corporation

Mr. Herve Hoppenot has made 3 insider trades between 2017-2021, according to the Form 4 filled with the SEC. Most recently he purchased 12,925 units of INCY stock on 23 Feb 2021.

The largest trade he's ever made was exercising 124,148 units of INCY stock on 26 Jun 2020. As of 23 Feb 2021 he still owns at least 284,231 units of INCY stock.

Transaction Date Security Shares Price per share Total value Source
Purchase
Common Stock 12,925 N/A N/A
Option
Incentive Stock Option (right to buy) 1,365 $110 $150,150
Option
Common Stock 89,771 $110 $9,874,810
Sale
Common Stock 1,365 $110 $150,150
Option
Common Stock 124,148 $83.73 $10,394,912
Option
Incentive Stock Option (right to buy) 4,647 $64.55 $299,964
Sale
Common Stock 4,647 $64.55 $299,964
Purchase
Common Stock 15,000 $60.94 $914,100
Sale
Common Stock 70,502 N/A N/A

Incyte key executives

Incyte Corporation executives and other stock owners filed with the SEC: